Reata Pharmaceuticals, Inc.
RETANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for RETA. That does not mean none is planned.
Get an email about RETA's next catalysts
Track Reata Pharmaceuticals (RETA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bardoxolone Methyl | Phase 2 | Covid19 | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Reata Pharmaceuticals, Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in Reata Pharmaceuticals, Inc.'s (RETA) pipeline across Phase 2. Its lead program is Bardoxolone Methyl (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Reata Pharmaceuticals, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Reata Pharmaceuticals, Inc. (RETA) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track RETA biotech catalysts?β
Add RETA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Reata Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
